1116240-01-7 Usage
General Description
2,4-dichloro-5-iodo-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine is a complex chemical compound with a molecular formula of C13H8Cl2IN3O2S. It consists of a pyrrolopyrimidine core with chlorine, iodine, and tosyl (p-toluenesulfonyl) groups attached at specific positions. 2,4-dichloro-5-iodo-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine is primarily used in pharmaceutical research and drug development due to its potential as a building block for various biologically active molecules. Its unique structure and reactivity make it a valuable tool in the synthesis of new drugs and pharmaceutical compounds. Additionally, it is being studied for its potential antimicrobial, antiviral, and antitumor properties, making it a promising candidate for future drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 1116240-01-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,1,6,2,4 and 0 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1116240-01:
(9*1)+(8*1)+(7*1)+(6*6)+(5*2)+(4*4)+(3*0)+(2*0)+(1*1)=87
87 % 10 = 7
So 1116240-01-7 is a valid CAS Registry Number.
1116240-01-7Relevant articles and documents
Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents
Gong, Chaochao,Huang, Jian,Liu, Yue,Tan, Hanyi,Zhang, Jiawei,Zhang, Qian
, (2021/07/02)
Focal adhesion kinase (FAK) is a ubiquitous intracellular non-receptor tyrosine kinase, which is involved in multiple cellular functions, including cell adhesion, migration, invasion, survival, and angiogenesis. In this study, a series of 7H-pyrrolo[2,3-d
PROTEIN KINASE INHIBITORS
-
Page/Page column 30-31, (2009/04/24)
Compounds, particularly compounds having spleen tyrosine kinase (Syk) inhibition activity, having the following structure: or a pharmaceutically acceptable salt thereof, wherein R1 is structure (a), (b), (c) or (d): and Ra, Rb, Rc, R2, R3, R4, R5, R6 and R7 are as defined herein. Methods associated with preparation and use of the same, as well as pharmaceutical compositions containing the same, are also disclosed, as well as uses of the same to treat a condition or disorder mediated by a Syk and/or JAK kinase.
